Next Article in Journal
COVID-19 Pneumonia on Post-Operative Day 2 after Esophagectomy: Performing Esophago-Gastric Junction Cancer Surgery during the SARS-Cov-2 Second Wave
Previous Article in Journal
Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
Open AccessReview

Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic

1
Department of Surgery, Grand River Hospital, Kitchener Waterloo, ON N2G 1G3, Canada
2
Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada
3
Division of Breast Imaging, Department of Diagnostic Imaging, University of Ottawa, Ottawa, ON K1H 8L6, Canada
4
Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada
5
Division of General Surgery, Department of Surgery, University of Ottawa, Ottawa, ON K1H 8L6, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(2), 1338-1347; https://doi.org/10.3390/curroncol28020127
Received: 2 January 2021 / Revised: 9 March 2021 / Accepted: 17 March 2021 / Published: 24 March 2021
Practice and behaviour change in healthcare is complex, and requires a set of critical steps that would be needed to implement and sustain the change. Neoadjuvant chemotherapy for breast cancer is traditionally used for locally advanced disease and is primarily advantageous for surgical downstaging purposes. However, it does also offer patients with certain biologic subtypes such as the triple negative or Her2 positive breast cancers the opportunity to improve survival, even in early stage disease. During the height of the pandemic, an opportunity and motivation for the increased use of neoadjuvant therapy in breast cancer was identified. This paper describes the conditions that have supported this practice change at the provider and institutional levels. We also include our own institutional algorithm based on tumor biology and extent of disease that have guided our decisions on breast cancer management during the pandemic. Our processes can be adapted by other institutions and breast oncology practices in accordance with local conditions and resources, during and beyond the pandemic. View Full-Text
Keywords: breast cancer; neoadjuvant chemotherapy; pandemic; practice change breast cancer; neoadjuvant chemotherapy; pandemic; practice change
Show Figures

Figure 1

MDPI and ACS Style

Tse, T.; Sehdev, S.; Seely, J.; Gravel, D.H.; Clemons, M.; Cordeiro, E.; Arnaout, A. Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic. Curr. Oncol. 2021, 28, 1338-1347. https://doi.org/10.3390/curroncol28020127

AMA Style

Tse T, Sehdev S, Seely J, Gravel DH, Clemons M, Cordeiro E, Arnaout A. Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic. Current Oncology. 2021; 28(2):1338-1347. https://doi.org/10.3390/curroncol28020127

Chicago/Turabian Style

Tse, Tabitha; Sehdev, Sandeep; Seely, Jean; Gravel, Denis H.; Clemons, Mark; Cordeiro, Erin; Arnaout, Angel. 2021. "Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic" Curr. Oncol. 28, no. 2: 1338-1347. https://doi.org/10.3390/curroncol28020127

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop